This company listing is no longer active
이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Medlab Clinical 과거 수익 실적
과거 기준 확인 0/6
Medlab Clinical's earnings have been declining at an average annual rate of -18.9%, while the Biotechs industry saw earnings growing at 19.6% annually. Revenues have been declining at an average rate of 19.2% per year.
주요 정보
-18.9%
수익 성장률
-7.9%
EPS 성장률
| Biotechs 산업 성장 | 9.6% |
| 매출 성장률 | -19.2% |
| 자기자본 수익률 | -108.3% |
| 순이익 | -541.7% |
| 최근 수익 업데이트 | 30 Jun 2022 |
최근 과거 실적 업데이트
Recent updates
Shareholders May Be More Conservative With Medlab Clinical Limited's (ASX:MDC) CEO Compensation For Now
Oct 06
Is Medlab Clinical (ASX:MDC) In A Good Position To Invest In Growth?
Oct 05What We Learned About Medlab Clinical's (ASX:MDC) CEO Pay
Feb 21Medlab Clinical (ASX:MDC) Share Prices Have Dropped 69% In The Last Three Years
Dec 30
Medlab Clinical Limited (ASX:MDC) Is Expected To Breakeven In The Near Future
Nov 22수익 및 비용 분석
Medlab Clinical 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.
수익 및 매출 내역
| 날짜 | 수익 | 수익 | G+A 비용 | R&D 비용 |
|---|---|---|---|---|
| 30 Jun 22 | 2 | -8 | 12 | 2 |
| 31 Mar 22 | 1 | -9 | 9 | 1 |
| 31 Dec 21 | 4 | -12 | 11 | 1 |
| 30 Sep 21 | 4 | -12 | 11 | 2 |
| 30 Jun 21 | 1 | -10 | 11 | 2 |
| 31 Mar 21 | 1 | -10 | 10 | 2 |
| 31 Dec 20 | 1 | -11 | 9 | 2 |
| 30 Sep 20 | 2 | -12 | 9 | 2 |
| 30 Jun 20 | 3 | -13 | 10 | 2 |
| 31 Mar 20 | 4 | -12 | 10 | 2 |
| 31 Dec 19 | 4 | -12 | 11 | 2 |
| 30 Sep 19 | 5 | -10 | 10 | 1 |
| 30 Jun 19 | 5 | -8 | 10 | 1 |
| 31 Mar 19 | 5 | -7 | 8 | 1 |
| 31 Dec 18 | 5 | -6 | 7 | 0 |
| 30 Sep 18 | 4 | -5 | 7 | 0 |
| 30 Jun 18 | 4 | -5 | 6 | 0 |
| 31 Mar 18 | 4 | -4 | 6 | 0 |
| 31 Dec 17 | 5 | -4 | 6 | 0 |
| 30 Sep 17 | 5 | -4 | 5 | 0 |
| 30 Jun 17 | 4 | -4 | 5 | 0 |
| 31 Mar 17 | 4 | -4 | 5 | 0 |
| 31 Dec 16 | 4 | -4 | 4 | 0 |
| 30 Sep 16 | 3 | -4 | 4 | 0 |
| 30 Jun 16 | 3 | -3 | 4 | 0 |
양질의 수익: MDC is currently unprofitable.
이익 마진 증가: MDC is currently unprofitable.
잉여현금흐름 대 수익 분석
과거 수익 성장 분석
수익추이: MDC is unprofitable, and losses have increased over the past 5 years at a rate of 18.9% per year.
성장 가속화: Unable to compare MDC's earnings growth over the past year to its 5-year average as it is currently unprofitable
수익 대 산업: MDC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.2%).
자기자본 수익률
높은 ROE: MDC has a negative Return on Equity (-108.25%), as it is currently unprofitable.